Difference between revisions of "Clomipramine-moclobemide"
From Psychiatrienet
| Line 10: | Line 10: | ||
* '''Day 15:''' start administration of moclobemide in a dosage of 150 mg/day. | * '''Day 15:''' start administration of moclobemide in a dosage of 150 mg/day. | ||
* '''Day 18:''' increase dosage of moclobemide to 300 mg/day. | * '''Day 18:''' increase dosage of moclobemide to 300 mg/day. | ||
| − | | | + | | caveat = |
| − | + | {{caveSS}} | |
| + | }} | ||
Revision as of 12:21, 28 July 2009
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from clomipramine to moclobemide.[1] [2]
Stop clomipramine - Before day 0: gradually reduce dosage of clomipramine to a maximum of 75 mg/ day.
- Day 1-7: reduce dosage of clomipramine to 25 mg/day.
- Day 8: stop administration of clomipramine.
Start moclobemide- Day 8-14: a wash-out period of one week is necessary.
- Day 15: start administration of moclobemide in a dosage of 150 mg/day.
- Day 18: increase dosage of moclobemide to 300 mg/day.
Cave- Occurrence of the serotonin syndrome is possible without wash-out period.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
